At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 25 enrolled
Drug / intervention
ombitasvir/paritaprevir/ritonavir +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Study to Evaluate Immune Restoration Following Removal of Viral Antigen in Treatment-Naïve and Treatment-Experienced Adults With Genotype (GT) 1a Chronic Hepatitis C Virus (HCV) Infection Administered Ombitasvir/ ABT-450/Ritonavir With Dasabuvir and Ribavirin (RBV) for 12 Weeks
In Brief
A Phase 3 clinical trial evaluating ombitasvir/paritaprevir/ritonavir, dasabuvir, and 1 other intervention for Chronic Hepatitis C and 2 related conditions. Completed, enrolled 25 participants.
Detailed Summary
A study to evaluate immune restoration following removal of viral antigen in non-cirrhotic hepatitis C virus (HCV) genotype (GT) 1a treatment-naïve and pegylated-interferon (pegIFN)/ribavirin (RBV) treatment-experienced adults receiving treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir coadministered with ribavirin (RBV) for 12 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedJun 2015
Primary CompletionAug 2016
Study CompletionDec 2016
TodayJul 2026
First PostedJun 19, 2015
Enrollment StartJun 1, 2015
Primary CompletionAug 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.0 years ago
Interventions
ombitasvir/paritaprevir/ritonavirdrug
ombitasvir/ABT-450/ritonavir tablets
dasabuvirdrug
dasabuvir tablets
ribavirindrug
ribavirin tablets